Patents by Inventor John P. Vu

John P. Vu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PAC1 RECEPTOR AGONISTS (MAXCAPS) AND USES THEREOF
    Publication number: 20220251162
    Abstract: In certain embodiments novel PAC1 receptor agonists are provided wherein the agonists comprise a targeting sequence that binds to the PAC1 receptor and said targeting sequence is attached to an amino acid sequence comprising a fragment of the maxadilan amino acid sequence, wherein the targeting sequence comprises a full-length 38 amino acid PACAP peptide or an N-terminus fragment thereof containing the amino acid sequence HSDGIF, wherein said targeting sequence optionally comprises an amino acid insertion between residues 11 and 12 of said PACAP peptide or fragment thereof; and the fragment of the maxadilan amino acid sequence comprises a fragment of the maxadilan sequence effective to activate PAC1 signaling.
    Type: Application
    Filed: October 25, 2021
    Publication date: August 11, 2022
    Applicants: The Regents of the University of California, The United States Government Represented by The Department Of Veterans Affairs
    Inventors: Joseph R. Pisegna, Patrizia M. Germano, John P. Vu
  • PAC1 receptor agonists (MAXCAPS) and uses thereof
    Patent number: 11186622
    Abstract: In certain embodiments novel PAC1 receptor agonists are provided wherein the agonists comprise a targeting sequence that binds to the PAC1 receptor and said targeting sequence is attached to an amino acid sequence comprising a fragment of the maxadilan amino acid sequence, wherein the targeting sequence comprises a full-length 38 amino acid PACAP peptide or an N-terminus fragment thereof containing the amino acid sequence HSDGIF, wherein said targeting sequence optionally comprises an amino acid insertion between residues 11 and 12 of said PACAP peptide or fragment thereof; and the fragment of the maxadilan amino acid sequence comprises a fragment of the maxadilan sequence effective to activate PAC1 signaling.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: November 30, 2021
    Assignees: The Regents of the University of California, The United States Covermment represented by the Department of Veterans Affairs
    Inventors: Joseph R. Pisegna, Patrizia M. Germano, John P. Vu
  • PAC1 RECEPTOR AGONISTS (MAXCAPS) AND USES THEREOF
    Publication number: 20190322718
    Abstract: In certain embodiments novel PAC1 receptor agonists are provided wherein the agonists comprise a targeting sequence that binds to the PAC1 receptor and said targeting sequence is attached to an amino acid sequence comprising a fragment of the maxadilan amino acid sequence, wherein the targeting sequence comprises a full-length 38 amino acid PACAP peptide or an N-terminus fragment thereof containing the amino acid sequence HSDGIF, wherein said targeting sequence optionally comprises an amino acid insertion between residues 11 and 12 of said PACAP peptide or fragment thereof; and the fragment of the maxadilan amino acid sequence comprises a fragment of the maxadilan sequence effective to activate PAC1 signaling.
    Type: Application
    Filed: January 4, 2018
    Publication date: October 24, 2019
    Inventors: Joseph R. Pisegna, Patrizia M. Germano, John P. Vu